Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Prabhu
Rajesh M
RM
Elliott
Michelle A
MA
Patel
Robin
R
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000627:therapeutic use*; D016470:Bacteremia / Q000150:complications / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000494:pharmacology; D005260:Female; D024841:Fluoroquinolones; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D000077266:Moxifloxacin; D009503:Neutropenia / Q000209:etiology; D015242:Ofloxacin / Q000494:pharmacology; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D011804:Quinolines / Q000627:therapeutic use*; D017211:Treatment Failure
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin